BTR (Boston Technology Research), a Chelsea, MA-based regulatory technology company serving healthcare, life sciences, and SaMD, announced that it raised $15 million in a Series A.
The round was led by New York-based global venture capital and private equity firm Insight Partners, with participation from LRV Health, NewStack Ventures, and other investors.
The new funding will be used to ensure that customers are prepared for the FDA’s anticipated guidance that will incentivize a move from traditional methods to new technologies.
Company: Boston Technology Research Corp.
Round: Series A
Funding Month: February 2022
Lead Investors: Insight Partners
Additional Investors: LRV Health and NewStack Ventures
Company Website: https://www.bostontr.com/
Software Category: SaaS-based validation lifecycle solution
About the Company: BTR is a leading regulatory technology company that automates how healthcare, life sciences, and SaMD companies establish and maintain compliance over their systems. BTR’s flagship solution, Res_Q (for Responsible_Quality), is an entirely digital, SaaS-based validation lifecycle solution that was born from the pain points of industry experience. It has been the compliance engine behind leading software vendors such as Veeva, Nuvolo, and Benchling, and has helped more than 275 healthcare and life sciences companies transition to the regulated cloud. BTR’s enterprise-wide compliance platform is used across leading software vendors and sponsors alike, including customers, like Glaukos, Dermavant, Lexicon, and Atsena. BTR is headquartered in Chelsea, MA, with a global workforce located throughout North America, Europe, and Asia.